Present status of accelerator-based BNCT: Focus on developments in Argentina

Cartelli, D.; Capoulat, M.E.; Bergueiro, J.; Gagetti, Leonardo; Anzorena, M. Suarez; Grosso, M.F. del; Baldo, M.; Castell, W.; Padulo, J.; Sandin, J.C. Suarez; Igarzábal, M.; Erhardt, J.; Mercuri, Daniel; Minsky, D.M.; Valda, A.A.; Debray, M. E.; Somacal, H.; Canepa, N.; Real, Nicolas; Gun, Marcelo; Herrera, María S.; Tacca, H.; Kreiner, Andrés J.

doi:10.1016/j.apradiso.2015.07.031

Cited by 22 publications

(6 citation statements)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…aspxospital). Others are in Russia using vacuum insulated tandem [53] and China Xiamen Humanity Hospital using the same machine, Argentina using electrostatic Quadrupole (ESQ) [54], and NUANS at Nagoya University in Japan using Dynamitron [55]. All projects other than Argentina use p-Li reaction and the Argentina project d-Be or d- 13 C.…”

Section: Boron Neutron Capture Therapymentioning

confidence: 99%

Neutron applications developing at compact accelerator-driven neutron sources

Kiyanagi

2021

AAPPS Bull.

View full text Add to dashboard Cite

Neutrons have been used in a wide field of applications by using various neutron sources. Material science is one of the widest research fields. The activity is supported by nuclear research reactors and high-intensity spallation neutron sources based on a high-intensity proton accelerator. However, it is desired to perform a measurement when researchers want to do and to perform adventuresome experiments that have not yet confirmed its importance. Furthermore, trial and error measurements are necessary to improve a measurement method. Compact accelerator-driven neutron sources are suitable for such usage and in some cases can complement the measurement at a large facility. The use of the compact neutron source has sometimes led to new methods. Other than material science, a new application of soft error acceleration test has been performed at the compact accelerator-driven neutron sources. Another neutron application is radiation therapy called as boron neutron capture therapy. In this field, nuclear reactor neutron sources have been used but many of them shut down. It was desired to construct the BNCT facility near a hospital. Therefore, BNCT facilities based on the compact accelerator have been constructed in the world. Here, the neutron sources and new methods and applications developing at compact accelerator-driven neutron sources are introduced.

show abstract

Section: Boron Neutron Capture Therapymentioning

confidence: 99%

Neutron applications developing at compact accelerator-driven neutron sources

Kiyanagi

2021

AAPPS Bull.

View full text Add to dashboard Cite

show abstract

“…BNCT uses 10 B neutron capture reaction that generates high linear energy α particles ( 4 He) and 7 Li nuclei with 2.4 MeV. The efficacy of BNCT relies on highly selective accumulation of 10 B in tumor cells. , In the last decade, accelerators have been developed for BNCT as a thermal neutron generator worldwide. − One of them was approved by Pharmaceutical and Medical Devices Agency (PMDA) in Japan as a medical device , in combination with l -4-boronophenylalanine ( l -BPA) for the treatment of head and neck carcinoma in March 2020. Therefore, the development of novel boron carriers applicable to various tumors suitable for BNCT, including tumors with low l -BPA accumulation, has emerged further requisite for BNCT.…”

Section: Introductionmentioning

confidence: 99%

Cyclic RGD-Functionalized closo-Dodecaborate Albumin Conjugates as Integrin Targeting Boron Carriers for Neutron Capture Therapy

et al. 2020

View full text Add to dashboard Cite

Cyclic RGD (cRGD) peptide-conjugated boronated albumin was developed to direct toward integrin αvβ3, which overexpresses on many cancer cells. A stepwise conjugation of c[RGDfK(Mal)] and maleimide-conjugated closo-dodecaborate (MID) to bovine serum albumin (BSA) afforded cRGD-MID-BSA, which was noncytotoxic toward both U87MG and A549 cells. As compared with l-BPA, selective antitumor activity of cRGD-MID-BSA toward U87MG cells overexpressing integrin αvβ3 was identified after thermal neutron irradiation. In vivo fluorescence live imaging of Cy5-conjugated cRGD-MID-BSA and MID-BSA revealed that both cRGD-MID-BSA and MID-BSA similarly reached the maximum accumulation during 8–12 h after injection. The selective accumulation and retention of Cy5-cRGD-MID-BSA was more pronounced than Cy5-MID-BSA after 24 h. An in vivo boron neutron capture therapy (BNCT) study revealed that the cRGD peptide ligand combination enhanced accumulation of MID-BSA into tumor cells in U87MG xenograft models. The significant tumor growth suppression was observed in U87MG xenograft models at a dose of 7.5 mg [10B]/kg after neutron irradiation.

show abstract

“…Therefore, the combination of boron agents with sufficient and selective accumulation of 10 B in cancer cells and an appropriate neutron source is essential for successful cancer treatment with BNCT [1,2]. In the last decade, accelerator-based thermal neutron generators for BNCT have been developed worldwide [3][4][5][6][7][8][9][10], and one was approved in Japan this year as a medical device [6,7] in combination with L-4-boronophenylalanine (L-BPA) [11] for the treatment of head and neck carcinoma patients. It is known that L-BPA is actively accumulated into cancer cells through L-type amino acid transporter 1 (LAT-1) [12,13], which is overexpressed in many cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Water-Soluble closo-Docecaborate-Containing Pteroyl Derivatives Targeting Folate Receptor-Positive Tumors for Boron Neutron Capture Therapy

Nakagawa

Kawashima

Morita

et al. 2020

Cells

View full text Add to dashboard Cite

Water-soluble pteroyl-closo-dodecaborate conjugates (PBCs 1–4), were developed as folate receptor (FRα) targeting boron carriers for boron neutron capture therapy (BNCT). PBCs 1–4 had adequately low cytotoxicity with IC50 values in the range of 1~3 mM toward selected human cancer cells, low enough to use as BNCT boron agents. PBCs 1–3 showed significant cell uptake by FRα positive cells, especially U87MG glioblastoma cells, although the accumulation of PBC 4 was low compared with PBCs 1–3 and L-4-boronophenylalanine (L-BPA). The cellular uptake of PBC 1 and PBC 3 by HeLa cells was arrested by increasing the concentration of folate in the medium, indicating that the major uptake mechanisms of PBC 1–3 are primarily through FRα receptor-mediated endocytosis.

show abstract

Present status of accelerator-based BNCT: Focus on developments in Argentina

Cited by 22 publications

References 15 publications

Neutron applications developing at compact accelerator-driven neutron sources

Neutron applications developing at compact accelerator-driven neutron sources

Cyclic RGD-Functionalized closo-Dodecaborate Albumin Conjugates as Integrin Targeting Boron Carriers for Neutron Capture Therapy

Water-Soluble closo-Docecaborate-Containing Pteroyl Derivatives Targeting Folate Receptor-Positive Tumors for Boron Neutron Capture Therapy

Contact Info

Product

Resources

About